Amneal Pharmaceuticals (AMRX) Income from Continuing Operations (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Income from Continuing Operations of 78000000.0 for Q1 2026, up 216.84% year-over-year from 24618000.0 in Q1 2025, and up 57.34% quarter-over-quarter from 49573000.0 in Q4 2025.
Amneal Pharmaceuticals (AMRX) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 78000000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 216.84% year-over-year to 78000000.0; the TTM figure through Mar 2026 stood at 181315000.0 (up 459.27% YoY), while the FY2025 annual figure was 127933000.0, up 273.17% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 78000000.0, up from 49573000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 78000000.0 in Q1 2026, with the low at 240081000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 11757000.0 (2024), against an average of 10086352.94.
- Peak annual rise in Income from Continuing Operations reached 1147.41% in 2023, while the deepest fall reached 1504.68% in 2023.
- Amneal Pharmaceuticals' Income from Continuing Operations stood at 5817000.0 in 2022, then plunged by 1504.68% to 93344000.0 in 2023, then soared by 77.78% to 20742000.0 in 2024, then surged by 339.0% to 49573000.0 in 2025, then surged by 57.34% to 78000000.0 in 2026.
- Business Quant data shows AMRX's Income from Continuing Operations at 78000000.0 in Q1 2026, 49573000.0 in Q4 2025, and 18132000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Amneal Pharmaceuticals | 5.72 Bn | 5.59 Bn | 334.51 Mn | 69.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.61 Mn |
| Mar 31, 2026 | 78.00 Mn |
| Dec 31, 2025 | 49.57 Mn |
| Sep 30, 2025 | 18.13 Mn |
| Jun 30, 2025 | 35.61 Mn |
| Mar 31, 2025 | 24.62 Mn |
| Dec 31, 2024 | -20.74 Mn |
| Sep 30, 2024 | 11.76 Mn |
| Jun 30, 2024 | 16.79 Mn |
| Mar 31, 2024 | -81.68 Mn |
| Dec 31, 2023 | -93.34 Mn |
| Sep 30, 2023 | 25.03 Mn |
| Jun 30, 2023 | 29.66 Mn |
| Mar 31, 2023 | -10.13 Mn |
| Dec 31, 2022 | -5.82 Mn |
| Sep 30, 2022 | -2.39 Mn |
| Jun 30, 2022 | -240.08 Mn |
| Mar 31, 2022 | -6.46 Mn |
| Dec 31, 2021 | -20.46 Mn |
| Sep 30, 2021 | -6.04 Mn |